Wancheng Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wancheng Liu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Xiangling Xing
Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, 250012, Shandong, People's Republic of China.
5 shared publications Chi Ma
Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, PR China
2 shared publicationsJiajun Gao
Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, PR China
2 shared publicationsYihong Wei
Department of Hematology, Qilu Hospital of Shandong University, Jinan, 250012, Shandong, PR China
2 shared publicationsZhixi Wei
Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, PR China
2 shared publicationsAmin Zhang
Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China
1 shared publication
Latest Publications
- Open Access
- 21 October 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
Protein acylation in cancer: from regulatory networks to precision therapeutics
Protein acylation comprises a diverse class of metabolite-responsive post-translational modifications that links cellular metabolic states to protein function and signaling. Beyond canonical acetylation, emerging acylation marks are dynamically controlled by acyl-donor availability and writer–eraser–reader systems, forming regulatory networks that reshape chromatin, metabolism, protein stability and localization, cytoskeletal dynamics, and immune responses. In cancer, dysregulated acylation enables tumor cells to adapt to metabolic and environmental stress, thereby promoting malignant progression, metastasis, immune escape, and therapeutic resistance. This Review examines the chemical and enzymatic principles of major protein acylations and integrates their roles across metabolic, epigenetic, signaling, and tumor-immune networks. We further discuss acylation-based biomarkers, patient stratification, pharmacological targeting, and mechanism-guided combination strategies, while highlighting challenges in modification specificity and clinical validation. Together, these advances position protein acylation as a regulatory interface between tumor plasticity and therapeutic response, providing a framework for biomarker-guided precision therapeutics.
- 21 October 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
Open AccessProtein acylation in cancer: from regulatory networks to precision therapeutics
Protein acylation comprises a diverse class of metabolite-responsive post-translational modifications that links cellular metabolic states to protein function and signaling. Beyond canonical acetylation, emerging acylation marks are dynamically controlled by acyl-donor availability and writer–eraser–reader systems, forming regulatory networks that reshape chromatin, metabolism, protein stability and localization, cytoskeletal dynamics, and immune responses. In cancer, dysregulated acylation enables tumor cells to adapt to metabolic and environmental stress, thereby promoting malignant progression, metastasis, immune escape, and therapeutic resistance. This Review examines the chemical and enzymatic principles of major protein acylations and integrates their roles across metabolic, epigenetic, signaling, and tumor-immune networks. We further discuss acylation-based biomarkers, patient stratification, pharmacological targeting, and mechanism-guided combination strategies, while highlighting challenges in modification specificity and clinical validation. Together, these advances position protein acylation as a regulatory interface between tumor plasticity and therapeutic response, providing a framework for biomarker-guided precision therapeutics.
- Open Access
- 9 May 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24
CELF family of RNA-binding proteins: roles in disease biology and potential for therapeutic intervention
The CUG-BP and Elav-like (CELF) family of RNA-binding proteins are key regulators of post-transcriptional gene expression, coordinating alternative splicing, mRNA stability, and translation. Although individual members, particularly CELF1 and CELF2, have been extensively characterized, a systematic, paralog-resolved integration of structural determinants, regulatory mechanisms, and disease relevance across all six CELF proteins remains limited. Here, we establish an integrative framework linking conserved RNA recognition motifs and divergent linker domains to context-dependent regulatory outputs, mediated by phosphorylation, nucleocytoplasmic dynamics, and RNA network interactions. We further highlight the neuron-enriched CELF3-CELF6 subfamily, consolidating emerging evidence that extends their roles beyond neural splicing into cancer-associated regulatory programs. Notably, we delineate functional divergence within the family, with CELF1 frequently acting as an oncogenic driver in contrast to the tumor-suppressive role of CELF2, while positioning less-characterized paralogs within this regulatory spectrum. Together, this work defines a unified structure-function-disease axis for CELF proteins and provides a conceptual framework for their prognostic and therapeutic exploitation. However, current CELF-targeted strategies remain largely preclinical and face key translational challenges, including paralog selectivity, off-target effects, and delivery barriers such as limited blood-brain barrier penetration. Accordingly, the most immediate clinical utility of CELF biology is likely to lie in biomarker development and patient stratification, rather than direct therapeutic intervention.
- 9 May 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24
Open AccessCELF family of RNA-binding proteins: roles in disease biology and potential for therapeutic intervention
The CUG-BP and Elav-like (CELF) family of RNA-binding proteins are key regulators of post-transcriptional gene expression, coordinating alternative splicing, mRNA stability, and translation. Although individual members, particularly CELF1 and CELF2, have been extensively characterized, a systematic, paralog-resolved integration of structural determinants, regulatory mechanisms, and disease relevance across all six CELF proteins remains limited. Here, we establish an integrative framework linking conserved RNA recognition motifs and divergent linker domains to context-dependent regulatory outputs, mediated by phosphorylation, nucleocytoplasmic dynamics, and RNA network interactions. We further highlight the neuron-enriched CELF3-CELF6 subfamily, consolidating emerging evidence that extends their roles beyond neural splicing into cancer-associated regulatory programs. Notably, we delineate functional divergence within the family, with CELF1 frequently acting as an oncogenic driver in contrast to the tumor-suppressive role of CELF2, while positioning less-characterized paralogs within this regulatory spectrum. Together, this work defines a unified structure-function-disease axis for CELF proteins and provides a conceptual framework for their prognostic and therapeutic exploitation. However, current CELF-targeted strategies remain largely preclinical and face key translational challenges, including paralog selectivity, off-target effects, and delivery barriers such as limited blood-brain barrier penetration. Accordingly, the most immediate clinical utility of CELF biology is likely to lie in biomarker development and patient stratification, rather than direct therapeutic intervention.
- 23 October 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 198 (Pt B) , 111227
NAT10-mediated ac4C-modified genes predict tumor prognosis and immune response in colon adenocarcinoma
- 23 October 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 198 (Pt B) , 111227
NAT10-mediated ac4C-modified genes predict tumor prognosis and immune response in colon adenocarcinoma
- Open Access
- 1 July 2025
- Published by KEAI Publishing in Genes & Diseases
- Vol. 12 (4) , 101489
IL-17 signaling pathway in SPP1+ macrophages drives digestive tract cancer progression
- 1 July 2025
- Published by KEAI Publishing in Genes & Diseases
- Vol. 12 (4) , 101489
Open AccessIL-17 signaling pathway in SPP1+ macrophages drives digestive tract cancer progression
- 4 April 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 309, 142797
STEAP Proteins: Roles in disease biology and potential for therapeutic intervention
- 4 April 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 309, 142797
STEAP Proteins: Roles in disease biology and potential for therapeutic intervention
- 20 January 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (7) , 1479-1490.e14
LPCAT1 Facilitates Keratinocyte Hyperproliferation and Skin Inflammation in Psoriasis by Regulating GLUT3
- 20 January 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (7) , 1479-1490.e14
LPCAT1 Facilitates Keratinocyte Hyperproliferation and Skin Inflammation in Psoriasis by Regulating GLUT3